New studies reveal rare but real risk of GLP-1 drugs
Health New studies reveal rare but real risk of GLP-1 drugs By Reuters Published July 23, 2026, 10:46 a.m. Add The New York Post on Google July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest. At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37 percent higher than in users of so-called SGLT-2 drugs and 68 percent higher versus DPP-4 drugs, researchers at the University of Pennsylvania reported on Wednesday in The BMJ.
- ▪Health New studies reveal rare but real risk of GLP-1 drugs By Reuters Published July 23, 2026, 10:46 a.m.
- ▪Add The New York Post on Google July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
- ▪At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37 percent higher than in users of so-called SGLT-2 drugs and 68 percent higher versus DPP-4 drugs, researchers at the University o
Opening excerpt (first ~120 words) tap to expand
Health New studies reveal rare but real risk of GLP-1 drugs By Reuters Published July 23, 2026, 10:46 a.m. ET (function() { var overlay = document.getElementById("nyp-player-lcp-overlay"); if (!overlay) { return; } function hideOverlay() { overlay.remove(); } function afterDCL() { requestAnimationFrame(hideOverlay); } if (document.readyState === "loading") { document.addEventListener("DOMContentLoaded", afterDCL, { once: true }); } else { afterDCL(); } })(); See more of our coverage in your search results. Add The New York Post on Google July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
